Isala Klinieken Stichting

Research site

The Netherlands Reggersweg 2, 7943 KC Meppel, The Netherlands

1 trial recruiting
Cerebral haemorrhage · Dyslipidaemia · Arteriosclerosis
Adult patients

About Specializations

Isala Klinieken Stichting in Meppel, The Netherlands specialises in clinical trials of conditions such as Cerebral haemorrhage, Dyslipidaemia, Arteriosclerosis, and other specialisations. This site conducts important research.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location

Reggersweg 27943 KC MeppelThe Netherlands

Open in maps ↗

Recruiting now: 1 trial
Conditions studied: 3

More sites in Meppel The Netherlands

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Quick filters

3 clinical trials

Cerebral haemorrhage

Recruiting

Study of clopidogrel and acetylsalicylic acid (aspirin) for prevention of cardiovascular events in patients who survived intracerebral hemorrhage stroke

Registered drugNo placebo

Study of clopidogrel and acetylsalicylic acid (aspirin) for prevention of cardiovascular events in patients who survived intracerebral hemorrhage stroke

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Acetylsalicylic Acid
Sponsor:University Of Edinburgh

Contact Research Centre

Dyslipidaemia

Not recruiting

Study of Evolocumab to Prevent Heart Disease Events in High-Risk Patients Without Previous Heart Attack or Stroke

Registered drug

Study of Evolocumab to Prevent Heart Disease Events in High-Risk Patients Without Previous Heart Attack or Stroke

Registered drug

The Netherlands

Participants:18–64 years · 65+ years
Substances:Evolocumab
Sponsor:Amgen Inc.

Contact Research Centre

Arteriosclerosis

Not recruiting

Study of inclisiran to prevent heart attacks and strokes in people with atherosclerotic cardiovascular disease

Registered drug

Study of inclisiran to prevent heart attacks and strokes in people with atherosclerotic cardiovascular disease

Registered drug

The Netherlands

Participants:18–64 years · 65+ years
Substances:Atorvastatin
Sponsor:Novartis Pharma AG

Contact Research Centre

Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites